EDX Medical to Market Pioneering Cancer Drugs Response Assay in UK and Nordics
2024年6月26日 - 5:21PM
ビジネスワイヤ(英語)
EDX Medical Group plc, which develops innovative digital
diagnostic products and services supporting personalised treatments
for cancer, heart disease and infectious diseases, announces today
it has signed an exclusive distribution agreement with Curesponse
Ltd, to market the cResponse™ cancer assay in the UK, Sweden,
Finland, Norway and Denmark.
cResponse™ is a groundbreaking platform that biologically
assesses how an individual patient’s living tumour tissue responds
to selected medicines, identifying the most effective treatment
options. It is the only clinical-grade technology providing
biological response data for chemotherapy, targeted biologics, and
immunotherapy drugs. This platform helps clinicians rapidly
pinpoint optimal treatments, potentially saving lives, reducing
treatment costs, and accelerating the discovery and development
cycles for pharmaceutical companies seeking new cancer drugs.
The cResponse™ platform generates a report ranking selected
cancer drugs based on their predicted effect on an individual
patient’s tumour, demonstrating over 90% accuracy in clinical
trials. The test can be augmented with rapid genomic sequencing to
identify additional drug candidates for functional analysis. The
entire process is powered by proprietary technologies and advanced
AI algorithms. The platform technology has been refined and
calibrated using thousands of cancer tissues, demonstrating its
clinical utility and effectiveness through hundreds of cases in
Israel and the UK. The cResponse™ test is performed at a United
Kingdom Accreditation Service (UKAS) accredited lab in London and
has also earned a CE mark for Europe, underscoring its regulatory
approval and readiness for clinical use.
EDX Medical will initiate commercial activities to support the
clinical use of the cResponse™ assay in the UK and Nordics with
immediate effect and will explore broadening the agreement with
Curesponse in due course.
Professor Sir Chris Evans, OBE, founder of EDX Medical plc,
commented: “We are delighted to be increasing accessibility to this
genuinely innovative and pioneering test which potentially offers
tremendous benefit to those treating cancer and their patients.
This product is an excellent addition to our rapidly growing
portfolio of class-leading diagnostic solutions.”
Dr Mike Hudson, CEO, EDX Medical plc, said: “We are very pleased
to have been selected by Curesponse as their partner, and to be
able to make their breakthrough assay available for our clients in
the UK and Nordics. We consider cResponse™ to be an outstanding
innovation in the fast-moving clinical cancer diagnostic
landscape.”
Guy Neev, CEO of Curesponse Ltd, commented: “We are thrilled to
partner with EDX Medical Group to bring our cResponse™ platform to
patients and clinicians in the UK and Nordic countries. Our mission
at Curesponse is to make this technology available to cancer
patients to optimize treatment outcomes and save lives. This
collaboration is a significant step toward achieving that goal. We
look forward to working closely with the EDX Medical team to ensure
the successful adoption and implementation of this groundbreaking
decision support tool.”
About EDX Medical Group plc
The EDX Medical Group plc is listed on the Apex Segment of the
AQSE Growth Market (TIDM: EDX). www.edxmedical.com
About Curesponse Ltd.
Curesponse is a pioneering leader in precision oncology.
www.curesponse.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240626860842/en/
EDX Medical plc Dr Mike Hudson (Chief Executive Officer)
+44 (0)7812 345 301
Media House International Ramsay Smith +44 (0)7788 414856
ramsay@mediahouse.co.uk Gary McQueen + 44 (0)7834 694609
gary@mediahouse.co.uk